CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer – East Meadow, NY
CDK 4/6 Inhibitors in HR+/HER2- Breast Cancer – East Meadow, NY
This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.